Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
For media and investors only
Issued: London, UK and Paris, France
- Discussions relate to vaccine candidate using Sanofi?s recombinant protein-based technology combined with GSK?s pandemic adjuvant system
- Both companies are committed to making their COVID-19 vaccine affordable and available globally